Author

L. G. Delogu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:machine learning (classical)· 1

Frequent Co-Authors

A. Yilmazer· 2 shared C. Gurcan· 1 shared F. Bayrakdar· 1 shared G. Saygili· 1 shared G. Y. Summak· 1 shared H. Nazir· 1 shared K. C. Akcali· 1 shared M. A. Unal· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

A. Yilmazer

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Predicting the Reprogrammability of Human Cells Based on Transcriptome Data and SGD Classifier with Elastic-Net Regularization

G. Saygili, M. Turktas, C. Gurcan, L. G. Delogu, A. Yilmazer

This study predicts cell reprogramming outcomes using transcriptome data and an SGD classifier with Elastic-Net regularization, achieving 98% accuracy and 0.98 AUC.

bioRxiv · Jul 18, 2022 · PreprintBioengineering

Favipiravir, umifenovir and camostat mesylate: a comparative study against SARS-CoV-2

M. A. Unal, O. Besbinar, H. Nazir, G. Y. Summak, F. Bayrakdar, L. G. Delogu, T. Taskin, S. A. Ozkan, K. C. Akcali, A. Yilmazer

This study compares the antiviral effects of favipiravir, umifenovir, and camostat mesylate against SARS-CoV-2 using in silico and in vitro methods, finding that combination treatments are more effective than single drugs.

bioRxiv · Jan 11, 2022 · PreprintPharmacology & Toxicology